
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Park et al.

Attorney Docket No.: BIZBP004X1

Application No.: Not Assigned

Examiner: Not Assigned

Filed: Herewith

Group: Not Assigned

Title: METHOD FOR INHIBITING TUMOR
ANGIOGENESIS AND TUMOR GROWTH

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents and/or fees referred to as attached therein are being deposited with the United States Postal Service on August 14, 2003 in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR §1.10, Mailing Label Number **EV332825033US**, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Ryan Eachus

**INFORMATION DISCLOSURE STATEMENT
37 CFR §§1.56 AND 1.97(b)**

Commissioner for Patents
Mail Stop New Application
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references listed in the attached PTO Form 1449, the required copies of which are attached, may be material to examination of the above-identified patent application.

Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

Yoshina *et al.*, 1977 and 1978 are forthcoming. The versions in Japanese are enclosed.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. BIZBP004X1).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP

A handwritten signature in black ink, appearing to read 'Reginald J. Suyat', written in a cursive style.

Reginald J. Suyat
Registration No. 28,172

P.O. Box 778
Berkeley, CA 94704-0778

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. BIZBP004X1	Application No.: Unknown
	Applicant: Park et al. Filing Date Herewith	Group Not Assigned

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	1A	6,518,294	02/11/03	Teng et al.			01/24/02
	1B	5,574,168	11/12/96	Kuo et al.			05/03/94
	1C	6,162,819	12/19/00	Schindler et al.			10/05/98

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	1D	10-2001-0060054	09/27/01	Republic of Korea			X	
	1E	0254241	07/18/87	EPO			X	
	1F	EP0667345	02/13/95	EPO			X	
	1G	EP1166785	06/19/01	EPO			X	

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	1H	Ko <i>et al.</i> , "YC-1 a Novel Activator of Platelet Guanylate Cyclase", <i>Blood</i> , Vol. 84, No. 12, December 15, 1994, pp. 4226-4233
	1I	Yeo <i>et al.</i> , "YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1", <i>Journal of the National Cancer Institute</i> , Vol. 95, No. 7, April 2, 2003, pp. 516-525
	1J	Höckel and Vaupel, "Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects", <i>Journal of National Cancer Institute</i> , Vol. 93, No. 4, February 21, 2001, pp. 266-276
	1K	Dachs and Tozer, "Hypoxia Modulated Gene Expression: Angiogenesis, Metastasis, and Therapeutic Exploitation", <i>European Journal of Cancer</i> , 36, May 2000, pp. 1649-1660
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (Modified)	Atty Docket No. BIZBP004X1	Application No.: Unknown
Information Disclosure Statement By Applicant	Applicant: Park et al.	
(Use Several Sheets if Necessary)	Filing Date Herewith	Group Not Assigned

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	2A	J. Martin Brown, "The Hypoxic Cell: A Target for Selective Cancer Therapy", Eighteenth Bruce F. Cain Memorial Award Lecture, <i>Cancer Research</i> , 59, December 1, 1999, pp. 5863-5870
	2B	Forsythe <i>et al.</i> , "Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1", <i>Molecular and Cellular Biology</i> , September 1996, pp. 4604-4613
	2C	Wang and Semenza, "Purification and Characterization of Hypoxia-Inducible Factor 1", <i>The Journal of Biological Chemistry</i> , Vol. 270, No. 3, January 20, 1995, pp. 1230-1237
	2D	Maxwell <i>et al.</i> , "The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis," <i>Nature</i> , Vol. 399, May 20, 1999, pp. 2710-275
	2E	Ivan <i>et al.</i> , "HIF α Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O ₂ Sensing", <i>Science</i> , Vol. 292, April 20, 2001, pp. 464-451
	2F	Masson <i>et al.</i> , "Independent Function of Two Destruction Domains In Hypoxia-Inducible Factor- α Chains Activated by Poly(ADP-ribose) Hydroxylation," <i>European Molecular Biology Organization, The EMBO Journal</i> , Vol. 20, No. 18, (2001) pp. 5197-5206
	2G	Huang <i>et al.</i> , "Regulation of Hypoxia-Inducible Factor 1 α is Mediated by an O ₂ -Dependent Degradation Domain Via the Ubiquitin-Proteasome Pathway," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 95, pp. 7987-7992, July 1998
	2H	Gregg L. Semenza, "HIF-1 and Tumor Progression: Pathophysiology and Therapeutics," <i>Trends in Molecular Medicine</i> , Vol. 8, No. 4, Suppl. (2002), pp. S62-S67
	2I	Zhong <i>et al.</i> , "Overexpression of Hypoxia-Inducible Factor 1 α in Common Human Cancers and Their Metastases", <i>Cancer Research</i> , Vol. 59, pp. 5830-5835, November 15, 1999
	2J	Birmer <i>et al.</i> , "Overexpression of Hypoxia-Inducible Factor 1 α Is a Marker For an Unfavorable Prognosis in Early-Stage Invasive Cervical Cancer", <i>Cancer Research</i> , Vol. 60, pp. 4693-4696, September 1, 2000
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. BIZBP004X1	Application No.: Unknown
	Applicant: Park et al. Filing Date Herewith	Group Not Assigned

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	3A	Maxwell <i>et al.</i> , "Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth", <i>Proc. Natl. Acad. Sci. USA</i> , Vol 94, pp. 8104-8109, July 1997 Medical Sciences
	3B	Teng <i>et al.</i> , "YC-1 A Ntric Oxide-Independent Activator of Soluble Guanylate Cyclase, Inhibits Platelet-Rich Thrombosis in Mice", <i>European Journal of Pharmacology</i> , Vol. 320, pp. 161-166, (1997)
	3C	Galle <i>et al.</i> , "Effects of the Soluble Guanylyl Cyclase Activator, YC-1, on Vascular Tone, Cyclic GMP Levels and Phosphodiesterase Activity", <i>British Journal of Pharmacology</i> ", Vol. 127, pp. 195-203 (1999)
	4D	Chun <i>et al.</i> , "Inhibitory Effect of YC-1 on the Hypoxic Induction of Erythropoietin and Vascular Endothelial Growth Factor in Hep3B Cells", <i>Biochemical Pharmacology</i> , Vol. 61, pp. 947-954 (2001)
	5E	Yoshina <i>et al.</i> , <i>Yakugaku Zasshi</i> , Vol. 98(2), pp. 204-209, (1978)
	5F	Yoshina <i>et al.</i> , <i>Yakugaku Zasshi</i> , Vol. 97(9), pp. 955-961, (1977)
	5G	Jaakkola <i>et al.</i> , "Targeting of HIF- α to the von Hippel –Lindau Ubiquitylation Complex by O ₂ -Regulated Prolyl Hydroxylation", <i>Science</i> , Vol. 292, pp. 468-472, April 20, 2001
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.